Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

British Journal of Cancer

Volumn 93, Issue 11, 2005, Pages 1209-1214

  Fossa S D ^a,j   Paluchowska, B ^b   Horwich, A ^c   Kaiser, G ^d   De Mulder, P H M ^e   Koriakine, O ^f   Van Oosterom, A T ^g   De Prijck, L ^h   Collette, L ^h   De Wit, R ⁱ  

^a UNIVERSITY OF OSLO   (Norway)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d KLINIKUM NÜRNBERG   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h EORTC DATA CENTER   (Belgium)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Bleomycin; Carboplatin; Cisplatin; Etoposide; Intermediate and poor prognosis metastatic germ cell tumours; Vincristine

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE;

EID: 27944486772     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602830     Document Type: Article

References (22)

1. Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, Baldetorp L, Ahlstrom S, Fossa SD (1991) Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 9: 818-826
2. Anthoney DA, Kaye SB (1999) Treatment of poor prognosis metastatic germ-cell tumours: much heat but, as yet, little light. Ann Oncol 10: 255-258
3. Bower M, Newlands ES, Holden L, Rustin GJS, Begent RHJ (1997) Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8: 477-483
4. Christian JA, Huddart RA, Norman A, Mason M, Fossa SD, Aass N, Nicholl EJ, Dearnaley DP, Horwich A (2003) Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 21: 871-877
5. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye SB (1999) Impact of treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91(10): 839-846
6. IV) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol 20: 184-188
7. Decatris MP, Wilkinson PM, Welch RS, Metzner M, Morgenstern GR, Dougall M (2000) High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 11: 427-434
8. De Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J (1999a) Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 83(6): 831-833
9. De Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L, Collette L, Sylvetser R (1998b) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-saeminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Tretament of Cancer. Br J Cancer 78(6): 828-832
10. Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ (2002a) A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol 13: 125-134
11. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ (2002b) Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86: 1555-1560
12. Germa-Lluch JR, Garcia del Muro X, Tabernero JM, Sanchez M, Aparicio J, Alba E, Barnadas A (1999) BOMB/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience. Ann Oncol 10(3): 289-293
13. Hartmann JT, Schleucher N, Metzner B (2002) Phase I/II study of sequential high dose VIP plus paclitaxel in poor prognosis germ cell tumors. Ann Oncol 13(suppl 5): 96 (abstract 348P)
14. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David-Crawford E, Vogelzang N, Trump D, Loehrer Sr PJ (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer 97: 1869-1875
15. Horwich A, Brada M, Nicholls J, Jay G, Hendry WF, Dearnaley D, Peckham MJ (1989a) Intensive induction chemotherapy for poor risk non seminomatous germ cell tumours. Eur J Cancer 25: 177-184
16. Horwich A, Dearnaley DP, Norman A, Nicolls J, Hendry WF (1994b) Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer 30: 1607-1611
17. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15(2): 594-603
18. Kaye SB, Mead GM, Fossa SD, Cullen M, deWit R, Bodrogi I, van-Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for research and treatment of cancer study. J Clin Oncol 16: 692-701
19. Rosti G, De Giorgi U, Wandt H, Lioure B, Leyvraz S, Kolbe K, Papiani G, Ballardini M, Kulekci A, Demirer T, Solid Tumours Working Party (2004) First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 34: 1033-1037
20. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083-4091
21. Sonneveld DJA, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT (2001) Improved long-term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91: 1304-1315
22. Wettlaufer JN, Feiner AS, Rosinson WA (1984) Vincristine, cisplatin and bleomycin with surgery in the management of advanced metastatic non seminomatous testis tumours. Cancer 53: 203-209